Showing 1351-1360 of 1616 results for "".
- Phase 3 Stage 1 DIAMOND Trial Results of Oculis' OCS-01 in DME Presented at Euretinahttps://modernod.com/news/phase-3-stage-1-diamond-trial-results-of-oculis-ocs-01-in-dme-presented-euretina/2481877/Oculis announced that Professor Ramin Tadayoni, MD, PhD, presented the positive results from stage 1 of the phase 3 DIAMOND trial of OCS-01 in patients with DME at the 23rd EURETINA congress in Amsterdam. The data showed that the trial met primary and secondary endpoints
- Amber Ophthalmics Announces First Patient Enrolled in Phase 2/3 Trial Evaluating Nexagon for the Treatment of PCEDhttps://modernod.com/news/amber-ophthalmics-announces-first-patient-enrolled-in-phase-23-trial-evaluating-nexagon-for-the-treatment-of-pced/2481785/Amber Ophthalmics announced that Mark S. Gorovoy, MD, has enrolled the first patient in the AMB-01-006 (NEXPEDE-1), a randomized, double-masked, vehicle-controlled phase 2/3 clinical trial designed to evaluate two concentrations of Nexagon (lufepirsen ophthalmic gel) for
- Reduction of Eyedrop Volume for Topical Ophthalmic Medications with the Nanodropper Bottle Adaptorhttps://modernod.com/news/reduction-of-eyedrop-volume-for-topical-ophthalmic-medications-with-the-nanodropper-bottle-adaptor/2481663/Nanodropper announced positive results from a research study conducted in collaboration with Leonard Seibold, MD, Professor of Ophthalmology at University of Colorado School of Medicine, which quantified eyedrop volume reduction and bottle life extension with the Nanodropper adaptor compared
- Aviceda Announces Dosing of First Patient With AVD-104, a Novel Glyco-Mimetic Nanoparticle for the Treatment of GAhttps://modernod.com/news/aviceda-announces-dosing-of-first-patient-with-avd-104-a-novel-glyco-mimetic-nanoparticle-for-the-treatment-of-ga/2481647/Aviceda Therapeutics announced the dosing of its first patient with AVD-104 in its phase 2 SIGLEC trial by Ashkan Abbey, MD, of Texas Retina Associates in Dallas. This lead intravitreal asset is a novel glycan-coated nanoparticle, supported by a uniquely strong preclinical in
- Dr. Louis R. Pasquale Winner of the Glaucoma Foundation's 2023 Robert Ritch Awardhttps://modernod.com/news/dr-louis-r-pasquale-winner-of-the-glaucoma-foundations-2023-robert-ritch-award/2481629/Louis R. Pasquale, MD, FARVO, has been named the 2023 recipient of The Glaucoma Foundation’s (TGF) Robert Ritch Award for Innovation and Excellence in Glaucoma. Created in 2008, the award recognizes the contributions of individuals who have played a significant and unique role in promoting
- Salvat Laboratories Presents Phase 3 Clinical Trials Results of Clobetasol Nanoemulsion for Treating Inflammation and Pain After Ocular Surgeryhttps://modernod.com/news/salvat-laboratories-presents-phase-3-clinical-trials-results-of-clobetasol-nanoemulsion-for-treating-inflammation-and-pain-after-ocular-surgery/2481604/Salvat Laboratories announced the results of phase 3 clinical trials of its ophthalmic corticosteroid at the Association for Research in Vision and Ophthalmology (ARVO) annual meeting in New Orleans. The studies’ global coordinator, Andrew Schwartz, MD, presented a poster outlinin
- Cellusion Announces First Patient Transplanted iPSC-Derived Corneal Endothelial Cell Substitute (CLS001)https://modernod.com/news/cellusion-announces-first-patient-transplanted-ipsc-derived-corneal-endothelial-cell-substitute-cls001/2481493/An iPS cell-derived corneal endothelial cell substitute (CLS001) was transplanted to the first patient, according to Cellusion. Research collaborator, Shigeto Shimmura, MD, PhD, Professor of Fujita Health University and Keio University in Japan, provided details of the procedure&nb
- Pioneers in Retinal Gene Therapies Awarded International Harrington Prizehttps://modernod.com/news/pioneers-in-retinal-gene-therapies-awarded-international-harrington-prize/2481453/The tenth annual Harrington Prize for Innovation in Medicine has been jointly awarded to Jean Bennett, MD, PhD, the F.M. Kirby Emeritus Professor of Ophthalmology and Cell and Developmental Biology at the Perelman School of Medicine at the University of Pennsylvania;
- Study: Iyuzeh Demonstrated Similar IOP Lowering Efficacy with a Favorable Safety Profile when Compared to Xalatanhttps://modernod.com/news/study-iyuzeh-demonstrated-similar-iop-lowering-efficacy-with-a-favorable-safety-profile-when-compared-to-xalatan-in-glaucoma-patients/2481450/Thea Pharma announced the presentation of phase 3 data on Iyuzeh (latanoprost ophthalmic solution 0.005%) by Jason Bacharach, MD, at the 2023 American Glaucoma Society (AGS) Annual Meeting. The large, pivotal clinical trial demonstrated comparable efficacy of preservative-free 
- Ocuphire Announces APX3330 Phase 2 Data Presentations at Retina Meetingshttps://modernod.com/news/ocuphire-announces-apx3330-phase-2-data-presentations-at-retina-meetings/2481416/Ocuphire Pharma announced two presentations featuring efficacy and safety results from the company’s recently completed ZETA-1 phase 2 trial of oral APX3330 in diabetic retinopathy (DR) at two medical meetings in February. Peter Kaiser, MD, Professor of Ophthalmology at the C